DZ2933A1 - Nouveaux composés azabicydilques à substitution hétéroaryl-éthyle/benzisoxazole, leur procédé de production et composition pharmaceutique les contenant. - Google Patents

Nouveaux composés azabicydilques à substitution hétéroaryl-éthyle/benzisoxazole, leur procédé de production et composition pharmaceutique les contenant.

Info

Publication number
DZ2933A1
DZ2933A1 DZ990233A DZ990233A DZ2933A1 DZ 2933 A1 DZ2933 A1 DZ 2933A1 DZ 990233 A DZ990233 A DZ 990233A DZ 990233 A DZ990233 A DZ 990233A DZ 2933 A1 DZ2933 A1 DZ 2933A1
Authority
DZ
Algeria
Prior art keywords
azabicydilic
benzisoxazole
ethyl
substituted
compounds
Prior art date
Application number
DZ990233A
Other languages
English (en)
French (fr)
Inventor
Gene Michael Bright
Kishor Amratlal Desai
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2933A1 publication Critical patent/DZ2933A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ990233A 1998-12-28 1999-11-10 Nouveaux composés azabicydilques à substitution hétéroaryl-éthyle/benzisoxazole, leur procédé de production et composition pharmaceutique les contenant. DZ2933A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28

Publications (1)

Publication Number Publication Date
DZ2933A1 true DZ2933A1 (fr) 2004-03-15

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990233A DZ2933A1 (fr) 1998-12-28 1999-11-10 Nouveaux composés azabicydilques à substitution hétéroaryl-éthyle/benzisoxazole, leur procédé de production et composition pharmaceutique les contenant.

Country Status (43)

Country Link
US (1) US6525196B1 (no)
EP (1) EP1140931B1 (no)
JP (1) JP2002533463A (no)
KR (1) KR100417506B1 (no)
CN (1) CN1332740A (no)
AP (1) AP2001002188A0 (no)
AR (1) AR024840A1 (no)
AT (1) ATE260278T1 (no)
AU (1) AU761711B2 (no)
BG (1) BG105710A (no)
BR (1) BR9916807A (no)
CA (1) CA2356985C (no)
CO (1) CO5150179A1 (no)
CR (1) CR6398A (no)
CZ (1) CZ291163B6 (no)
DE (1) DE69915113T2 (no)
DK (1) DK1140931T3 (no)
DZ (1) DZ2933A1 (no)
EA (1) EA003099B1 (no)
EE (1) EE04439B1 (no)
ES (1) ES2214892T3 (no)
GE (1) GEP20043227B (no)
GT (1) GT199900224A (no)
HR (1) HRP20010488A2 (no)
HU (1) HUP0104852A3 (no)
ID (1) ID30117A (no)
IL (1) IL143385A0 (no)
IS (1) IS5951A (no)
MA (1) MA26706A1 (no)
NO (1) NO20013215L (no)
NZ (1) NZ511964A (no)
OA (1) OA11742A (no)
PA (1) PA8486701A1 (no)
PE (1) PE20001234A1 (no)
PT (1) PT1140931E (no)
SK (1) SK9002001A3 (no)
TN (1) TNSN99218A1 (no)
TR (1) TR200101979T2 (no)
TW (1) TW523514B (no)
UA (1) UA62015C2 (no)
WO (1) WO2000039128A1 (no)
YU (1) YU44301A (no)
ZA (1) ZA200105041B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
MXPA05009660A (es) * 2003-03-12 2005-10-20 Pfizer Prod Inc Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
WO2005082370A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
BRPI0514793A (pt) * 2004-09-10 2008-06-24 Pfizer Prod Inc uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos
MX2007002460A (es) * 2004-09-10 2007-05-04 Pfizer Prod Inc Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
US20230057844A1 (en) * 2019-12-20 2023-02-23 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
BR9809092A (pt) * 1997-04-18 2002-01-22 Smithkline Beecham Plc Derivados de indol tendo atividade combinada de antagonista de receptor de 5ht1a, 5ht1b e 5ht1d
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
CA2356985A1 (en) 2000-07-06
HRP20010488A2 (en) 2002-08-31
OA11742A (en) 2005-05-13
UA62015C2 (en) 2003-12-15
NO20013215D0 (no) 2001-06-27
CZ291163B6 (cs) 2003-01-15
US6525196B1 (en) 2003-02-25
WO2000039128A1 (en) 2000-07-06
HUP0104852A2 (hu) 2002-05-29
CA2356985C (en) 2006-08-08
YU44301A (sh) 2004-07-15
DK1140931T3 (da) 2004-04-19
PE20001234A1 (es) 2000-11-07
KR100417506B1 (ko) 2004-02-05
CZ20012386A3 (cs) 2002-02-13
AU761711B2 (en) 2003-06-05
CO5150179A1 (es) 2002-04-29
SK9002001A3 (en) 2002-04-04
GEP20043227B (en) 2004-04-26
IS5951A (is) 2001-05-22
HUP0104852A3 (en) 2002-12-28
EE200100346A (et) 2002-12-16
BR9916807A (pt) 2001-10-23
AP2001002188A0 (en) 2001-06-30
CR6398A (es) 2004-03-24
EA003099B1 (ru) 2002-12-26
GT199900224A (es) 2001-06-15
EE04439B1 (et) 2005-02-15
EP1140931B1 (en) 2004-02-25
CN1332740A (zh) 2002-01-23
JP2002533463A (ja) 2002-10-08
IL143385A0 (en) 2002-04-21
EP1140931A1 (en) 2001-10-10
PA8486701A1 (es) 2000-09-29
NO20013215L (no) 2001-08-27
TW523514B (en) 2003-03-11
DE69915113T2 (de) 2004-08-26
ES2214892T3 (es) 2004-09-16
AR024840A1 (es) 2002-10-30
PT1140931E (pt) 2004-05-31
MA26706A1 (fr) 2004-12-20
NZ511964A (en) 2003-08-29
TR200101979T2 (tr) 2001-12-21
BG105710A (en) 2002-02-28
TNSN99218A1 (fr) 2005-11-10
ATE260278T1 (de) 2004-03-15
ID30117A (id) 2001-11-08
DE69915113D1 (de) 2004-04-01
ZA200105041B (en) 2002-06-20
KR20010092455A (ko) 2001-10-25
AU6361499A (en) 2000-07-31
EA200100517A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2697A1 (fr) Composés azapolycycliques à noyau aryle condensé procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2933A1 (fr) Nouveaux composés azabicydilques à substitution hétéroaryl-éthyle/benzisoxazole, leur procédé de production et composition pharmaceutique les contenant.
DZ2978A1 (fr) Composés chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3000A1 (fr) Macrolides nouveaux, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2944A1 (fr) Azalides nouveaux, procédé our leur préparation etcompositions pharmaceutiques les contenant.
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2567131B1 (fr) Nouveaux derives de ganglioside, procede pour leur obtention et composition pharmaceutique les contenant
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2655A1 (fr) Trifluorométhyléthers cycliques à fonction pipéridinylaminoéthyle procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2796A1 (fr) Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26552A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26642A1 (fr) Derives de sulfonylbenzene nouveaux, procédé pour leur preparation et compositions pharmaceutiques les contenant.
DZ2756A1 (fr) Composés azabicycliques substitués nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.